Compare Mesoblast Limited (MESO) vs Nerdwallet Inc (NRDS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Nerdwallet Inc — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while Nerdwallet Inc trades at $9.74 (market cap $625.17M). The key difference: Mesoblast Limited is far larger — about 2.8× Nerdwallet Inc's market cap, and Nerdwallet Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Nerdwallet Inc for 45 Days on average.
| MESO | NRDS | |
|---|---|---|
Market Cap | $1.75B | $625.17M |
Volume | 239,027 | 1,321,316 |
Sector | Health | Media |
52-Week High | $20.96 | $15.93 |
52-Week Low | $13.19 | $7.58 |
Typical Hold Time | 15 Days | 45 Days |
Enterprise Value | $1.83B | $539.47M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mesoblast (MESO) trades at $13.75, down 1.36% with bearish technical signals despite recent FDA approval for its Ryoncil potency assay. The company shows significant revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent milestones include completing Phase 3 trials for chronic back pain treatment, positioning the biotech firm for potential market expansion in the $10 billion back pain market.
Investment outlook balances promising commercial progress against persistent financial losses. The stock offers speculative growth potential through FDA-approved therapies and pipeline developments, but carries substantial risk from ongoing cash burn and competitive pressures in the regenerative medicine space.
NerdWallet (NRDS) trades at $9.79, up 7.76% in 24 hours, with a bullish technical signal and strong profitability metrics including a 93.5% gross margin and 18.16% ROE. Recent earnings showed a Q2 2026 miss but beats in prior quarters, while revenue growth is robust, rising from $539M in 2022 to $837M in 2025. Positive cash flow trends and analyst consensus support a favorable outlook.
The stock presents a compelling value with a P/E of 10.87 and P/S of 0.81, though risks include reliance on organic search traffic and economic sensitivity. Analyst sentiment is bullish with 67% buy ratings, targeting upside potential. Continued execution on revenue growth and margin expansion are key catalysts for further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →
